SimBioSys Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5.25M

  • Investors
  • 11

SimBioSys General Information

Description

Developer of a medical platform intended to deploy computational oncology to transform decision-making and patient experience in cancer care. The company's offerings include comprehensive datasets collected during diagnosis into personalized virtual tumors through computational scenario analysis, enabling doctors to provide a better understanding of the disease and get treated accordingly.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 320 North Sangamon Street
  • 7th floor
  • Chicago, IL 60607
  • United States
+1 (872)
Primary Industry
Decision/Risk Analysis
Corporate Office
  • 320 North Sangamon Street
  • 7th floor
  • Chicago, IL 60607
  • United States
+1 (872)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SimBioSys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 06-Jan-2025 $5.25M Completed Generating Revenue
4. Grant 18-Nov-2022 Completed Generating Revenue
3. Early Stage VC (Series A) 20-Jul-2021 Completed Generating Revenue
2. Seed Round 20-Nov-2018 $900K $900K Completed Startup
1. Grant 01-Jan-2017 $212K Completed Startup
To view SimBioSys’s complete valuation and funding history, request access »

SimBioSys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view SimBioSys’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SimBioSys Patents

SimBioSys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260207121-A1 Multi-tissue segmentation and deformation for breast cancer surgery Pending 06-Dec-2022
WO-2024123484-A1 Multi-tissue segmentation and deformation for breast cancer surgery Inactive 06-Dec-2022
US-20250046452-A1 A method for cancer prognostication using perfusion kinetic analysis of standard-of-care dce mris Pending 06-Dec-2021
WO-2023107518-A1 A method for cancer prognostication using perfusion kinetic analysis of standard-of-care dce mris Inactive 06-Dec-2021
WO-2023081000-A1 Metabolic modeling for disease prognosis and treatment Inactive 03-Nov-2021 G16H50/50
To view SimBioSys’s complete patent history, request access »

SimBioSys Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SimBioSys Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Calculus Venture Capital Venture Capital Minority
Xcellerant Ventures Venture Capital Minority
National Cancer Institute I-Corps Accelerator/Incubator
AV8 Ventures Venture Capital Minority
Genoa Ventures Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

SimBioSys FAQs

  • When was SimBioSys founded?

    SimBioSys was founded in 2017.

  • Where is SimBioSys headquartered?

    SimBioSys is headquartered in Chicago, IL.

  • What is the size of SimBioSys?

    SimBioSys has 30 total employees.

  • What industry is SimBioSys in?

    SimBioSys’s primary industry is Decision/Risk Analysis.

  • Is SimBioSys a private or public company?

    SimBioSys is a Private company.

  • What is SimBioSys’s current revenue?

    The current revenue for SimBioSys is .

  • How much funding has SimBioSys raised over time?

    SimBioSys has raised $21.1M.

  • Who are SimBioSys’s investors?

    Calculus Venture Capital, Xcellerant Ventures, National Cancer Institute I-Corps, AV8 Ventures, and Genoa Ventures are 5 of 11 investors who have invested in SimBioSys.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process